Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Tiziana Life Sciences Ltd.

< Previous 1 2 Next >
Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer’s Disease
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Ltd. Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to File Alzheimer’s IND for Intranasal Foralumab in Q2 2023
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Initiates Program to Develop Intranasal Foralumab in Type 1 Diabetes
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO
From Tiziana Life Sciences Ltd.
Via GlobeNewswire
Tickers TLSA
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.